Clinical Gastroenterology and Hepatology

Article	Citations
Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease	388
Reply	310
Gastrointestinal Eosinophil Responses in a Longitudinal, Randomized Trial of Peanut Oral Immunotherapy	268
Effects of Rome IV Definitions of Functional Dyspepsia Subgroups in Secondary Care	209
Barrett’s Esophagus Risk Factors in Patients Without Gastroesophageal Reflux: A Large Population-Based Study	200
Endoscopic Polypectomy: How Should We Determine Complete Resection Status?	200
Look for a Physical Health Status Surrogate in Hepatocellular Carcinoma: Have we Found the Holy Grail?	195
Low Daily Step Count Is Associated With a High Risk of Hospital Admission and Death in Community-Dwelling Patients With Cirrhosis	192
Simplifying ADR Reporting: A Worthy Goal, but the Devil is in the Details	189
An Unexpected Subepithelial Lesion: Catching the Diagnosis Earlier!	177
Familial Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study in South Korea	160
Reply	153
Gastric Emphysema With Hepatic Portal Venous Gas Secondary to Acute Gastric Mucosal Lesion	149
HBV RNA, Hepatitis B Core-Related Antigen, and Quantitative Hepatitis B Surface Antigen Biomarkers to Predict Outcome of Antiviral Therapy	148
Editorial Board	142
Relative Cost-effectiveness of Management Strategies for Uninvestigated Dyspepsia	140
Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study	135
Assessment and Significance of Histologic Activity in Crohn’s Disease	132
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease	128
Attribution of Colonoscopy Risk Does Not FIT!	127
The Evolving Landscape of Colorectal Cancer Screening and Colonoscopy Practice: Insights From the Japan Polyp Study	125
Reply	125
Exam 1: Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis	124
A Case of Pedunculated Esophageal Neuroendocrine Tumor G1	117
Table of Contents	116

Cover	112
Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With CHB: A Comment for Moving Forward	107
Hyperbaric Oxygen Therapy Is Effective in the Treatment of Inflammatory and Fistulizing Pouch Complications	104
Issue Highlights	104
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis	103
Elsewhere in the AGA Journals	103
Correction	101
FODMAPs in IBS: Revisiting Restriction	100
Hepatic Artery Pseudoaneurysm After Whipple Procedure	100
Blue Notes	99
Long-term Effectiveness and Safety of Risankizumab in Patients with Crohn’s Disease	97
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA	94
Australasian Insights and Perspectives on the Burden of Chronic Liver Disease	89
Fecal Microbiota Transplantation (FMT) in Ulcerative Colitis: Holding Out for a Superdonor?	89
Frequent Abnormal Pancreas Imaging in Patients With Pathogenic ATM, BRCA1, BRCA2, and PALB2 Breast Cancer Susceptibility Variants	85
Genetic Diagnosis Guides Treatment of Autoimmune Enteropathy	85
Fecal Immunochemical Tests: The Right Colorectal Cancer Screening Test for the Average-Risk Population?	85
Aseptic Abscess Syndrome With Ulcerative Colitis and Pyoderma Gangrenosum	84
Natural History of Patients Lost to Follow-up After Esophageal Food Impaction	84
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study	83
Disaggregating Racial and Ethnic Data: A Step Toward Diversity, Equity, and Inclusion	83
Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment	83
Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials	82
A Novel, Noninvasive Method to Diagnose Active Eosinophilic Esophagitis, Combining Clinical Data and Oral Cavity RNA Levels	82
Development of a Simple, Point-of-Care Device to Test Anorectal Function in Patients with Constipation: Randomized Clinical Trial	81
Relationship Between Gastric Emptying Rate and Simultaneously Assessed Symptoms in Functional Dyspepsia	80
Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicentre, Sham-controlled, Randomized Trial	80
Association of Statin Usage and the Development of Diabetes Mellitus after Acute Pancreatitis	79
Low Incidence of Pulmonary Aspiration During Upper Endoscopy in Patients Prescribed a Glucagon-Like Peptide 1 Receptor Agonist	78
Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis	78
Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling	78
Overall and Annual Postcolonoscopy Colorectal Cancer Rates in a Large Integrated Healthcare Setting: A Cross-Sectional Study	77
Fibrosis-4 Index Predicts Long-Term All-Cause, Cardiovascular and Liver-Related Mortality in the Adult Korean Population	77
Gut Microbiome Modulation by Antibiotics in Adult Asthma: A Human Proof-of-Concept Intervention Trial	75
Front Cover	74
The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease	74
Editorial Board	74
Health Disparities in Inflammatory Bowel Disease Care Driven by Rural Versus Urban Residence: Challenges and Potential Solutions	74
Sugar-Sweetened Beverage, Diet Soda, and Nonalcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study	74
AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus: Expert Review	73
High Hospitalization Rates and Risk Factors Among Frail Patients With Cirrhosis: A 10-year Population-based Cohort Study	72
Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis	72
Prevalence of Gastric Precursor Lesions in Countries With Differential Gastric Cancer Burden: A Systematic Review and Meta-analysis	71
An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States	71
The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy	68
Daily or Twice Daily Treatment With Topical Steroids Results in Similar Responses in Eosinophilic Esophagitis	66
An Unsuccessful Randomized Trial of Percutaneous vs Endoscopic Drainage of Suspected Malignant Hilar Obstruction	66
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary	66
Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study	65
Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis	65

Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn’s Disease: A Systematic Review and Meta-analysis	65
In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent	65
Update in the Treatment of the Complications of Cirrhosis	63
Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability	63
National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States	63
Metabolic Signatures of Healthy Lifestyle Patterns and Colorectal Cancer Risk in a European Cohort	63
AGA Clinical Practice Update on Endoscopic Management of Perforations in Gastrointestinal Tract: Expert Review	63
An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI	63
Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States	63
Blue Notes	62
Foaming at the Varix: Sclerotherapy of Esophageal Varices via Intrahepatic Portal Vein Access	61
Information for Authors and Readers	61
Reply	61
Editorial Board	59
Reply	59
Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges	59
Information for Authors and Readers	58
Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies	58
Reply	58
Issue Highlights	58
Cover	58
A Framework for Creating a FOAMed Organization in Gastroenterology: Lessons Learned from the Liver Fellow Network	57
Direct Oral Anticoagulants in Budd-Chiari Syndrome: Need a Closer Look!	57
Reply	57
Information for Authors and Readers	56
Editorial Board	56
Close Observation of the Lateral Walls of the Oropharynx During Esophagogastroduodenoscopy	56
Reply	56
Table of Contents	55
Bowel Perforation by Intrauterine Device	55
Von Willebrand Factor Level Indicate Response to β-Blockers in Cirrhosis: Need a Closer Look!	54
Environmental Toxins in Breast Milk and Risk of Early Onset Colorectal Cancer	54
Transient Uterine Prolapse: A Rare Complication of Endoscopic Polypectomy	54
Cover	54
Editorial Board	54
Health Policy Priorities for the Biden Administration	54
Statins for Chronic Liver Disease and the Need for Randomized Controlled Trials	53
Unusual Presentation of a Crohn’s Disease Patient: Not Your Typical Flare	52
Editorial Board	52
Table of Contents	52
Reply	52
Reply	52
Nonrecurrence Rate of Underwater EMR for ≤20-mm Nonampullary Duodenal Adenomas: A Multicenter Prospective Study (D-UEMR Study)	51
Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey	51
Risk of Cancer in Biopsy-Proven Alcohol-Related Liver Disease: A Population-Based Cohort Study of 3410 Persons	51
Development of a Practical Guide to Implement and Monitor Diet Therapy for Eosinophilic Esophagitis	51
Needle Track Seeding After Trans-gastric EUS-guided Tissue Sampling: Maybe not as Rare as You Think	51
Two vs One Forward View Examination of Right Colon on Adenoma Detection: An International Multicenter Randomized Trial	51
Real-World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn’s Disease	51
Assessing Diagnostic Performance of Modifications to the Rome IV Criteria for Irritable Bowel Syndrome	51
A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis	51
Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations	50
Distinct Clinical Physiologic Phenotypes of Patients With Laryngeal Symptoms Referred for Reflux Evaluation	50
Prolonged Gastrointestinal Manifestations After Recovery From COVID-19	49
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis	49
Multiple Negative Fecal Immunochemical Tests: Is Testing Really Better?	49
All-cause and cause-specific mortality in achalasia: A nationwide matched cohort study	49
Acute-onset Type 1 Diabetes Mellitus and Pancreatic Atrophy Caused by an Immune Checkpoint Inhibitor	49
Skills or Pills: Randomized Trial Comparing Hypnotherapy to Medical Treatment in Children With Functional Nausea	48
Low Colorectal Cancer Risk After Resection of High-Risk Pedunculated Polyps	48
Perianal Fistulizing Crohn’s Disease–Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus	48
Continuous Risk Score Predicts Waitlist and Post-transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes	48
North American Expert Consensus on the Post-procedural Care of Patients After Per-oral Endoscopic Myotomy Using a Delphi Process	48
Distinctive Clinical Correlates of Small Intestinal Bacterial Overgrowth with Methanogens	48
Reply	47
Population-based Screening for Hereditary Colorectal Cancer Variants in Japan	47
Continuing the Commitment to Diversity, Equity, and Inclusion Within AGA Journals	47
Correction	47
Harm-to-Benefit Ratio of Fecal Immunochemical Test–Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations	47
Bouveret Syndrome Treated With Endoscopic Lithotripsy and Gallbladder Access via Cholecysto-duodenal Fistula	46
Front Cover	46
Hurdles in ERCP Trials: Do We Need to Change the Diagnostic Criteria for Post-ERCP Pancreatitis?	46
Uptake of Colorectal Cancer Screening in 45 to 49 Year Olds: An Early-Inning View from the Endoscopy Suite	45
Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study	45
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn’s Disease	45
Exploring the Early Phase of Crohn’s Disease	45
Reply	45
Colon Volume by Computed Tomography and Scintigraphic Colonic Transit in Constipated Patients With or Without Redundant Colon	45
Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease	44
Preoperative Hepatology and Primary Care Visits Improve Postoperative Outcomes in Patients With Cirrhosis Undergoing Surgery	44

Constrictive and Hypertrophic Strictures in Ileal Crohn’s Disease	44
The New Kids on the Block: Emerging Complementary Colonoscopy Quality Metrics	44
Value of Ammonia Testing in Clinical Practice	43
Weight Change and the Development of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Overweight Individuals	43
Diverticulosis Is Associated With Internal Hemorrhoids on Colonoscopy: Possible Clues to Etiology	43
Reply	43
Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network	43
The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population	43
Avoidant Restrictive Food Intake Disorder Prevalent Among Patients With Inflammatory Bowel Disease	43
Measuring Quality in Barrett’s Endoscopy	43
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study	42
Adenoma Detection Rate (ADR) Irrespective of Indication Is Comparable to Screening ADR: Implications for Quality Monitoring	42
Primary Sclerosing Cholangitis–Associated Pouchitis: A Distinct Clinical Phenotype	42
Significance of Crypt Atypia in Barrett’s Esophagus: A Clinical, Molecular, and Outcome Study	42
Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma	42
Deficits in Geriatric Assessment Associate With Disease Activity and Burden in Older Patients With Inflammatory Bowel Disease	42
Clinical Outcomes of Intraductal Papillary Mucinous Neoplasms With Dilatation of the Main Pancreatic Duct	42
Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion	42
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis	41
The Severity of Reduced Esophageal Distensibility Parallels Eosinophilic Esophagitis Disease Duration	41
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update	41
Diet and Microbiome-Directed Therapy 2.0 for IBD	41
Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis	41
Birth Cohort Colorectal Cancer (CRC): Implications for Research and Practice	40
Reply	40
Adenoma Detection Rate and Clinical Characteristics Influence Advanced Neoplasia Risk After Colorectal Polypectomy	40
Elsewhere in the AGA Journals	40
Table of Contents	40
Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults	40
Reply	40
Neoplasia Detection Rate in Barrett’s Esophagus and Its Impact on Missed Dysplasia: Results from a Large Population-Based Database	39
Porcelain Gallbladder	39
Letter Response to: Hernandez-Rocha C et al, Clin Gastroenterol Hepatol 2024	39
Reply	39
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat	38
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease	38
Prevalence of Chronic Liver Disease in Cholangiocarcinoma: A Meta-Analysis	38
Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999–2018	38
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis	38
Supplementing Dietary Fibers With a Low FODMAP Diet in Irritable Bowel Syndrome: A Randomized Controlled Crossover Trial	38
Prediction of Postoperative Recurrence in Crohn’s Disease: Where Do We Go From Here?	38
Clinical, Pathology, Genetic, and Molecular Features of Colorectal Tumors in Adolescents and Adults 25 Years or Younger	38
Psychiatric Comorbidities Are Highly Prevalent in Nonesophageal Eosinophilic Gastrointestinal Diseases	38
Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease	38
Defining radiological healing in perianal fistulising Crohn’s Disease: a TOpClass global expert Delphi consensus	38
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis	38
Endoscopic Sedation Type During FLIP Panometry Does Not Significantly Impact FLIP Motility Classification Relative to Manometry	38
Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study	37
Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate	37
Linked-Color Imaging Detects More Colorectal Adenoma and Serrated Lesions: An International Randomized Controlled Trial	37
Depression and Anxiety Are Common Among Patients With Cirrhosis	37
Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease	37
Characteristics and Risk Factors of Post-Infection Irritable Bowel Syndrome After Campylobacter Enteritis	37
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis	37
Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension	37
Bleeding Gastric Teratoma on Adult Patient	37
Crafting a Therapeutic Pyramid for Eosinophilic Esophagitis in the Age of Biologics	36
Stratifying Risks of Ileal Pouch Outcomes	36
To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn’s Disease	36
Editorial Board	36
AGA Clinical Practice Update on Endoscopic Lifting Agents: Commentary	36
Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet	36
Blue Notes	36
The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude	36
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease	36
Reply	36
Lymphangioma in a Child Managed With Debulking Surgery	35
Front Cover	35
Editorial Board	35
Information for Authors and Readers	35
Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma With Varices Using Red Dichromatic Imaging	35
Adult-Onset Fontan Circuit Failure: A Rare Cause of Protein-Losing Enteropathy	35
Reply	35
Blue Notes	35
Reply	35
Ustekinumab and Vedolizumab Safety and Clearance in Pregnancy With Inflammatory Bowel Disease: Stop the Disease, Not the Drug!	34
Disparities in Colorectal Cancer Screening Among Asian American Populations and Strategies to Address These Disparities	34
Preparing the Next Generation of Gastroenterologists to Tackle Climate Change	34
Editorial Board	34
Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases	34
Incomplete Response of Gastroesophageal Reflux Symptoms Poorly Predicts Erosive Esophagitis or Barrett’s Esophagus	33
Reply	33
Reply to “Kidney Failure, Inflammatory Bowel Disease, and Colectomy”	33
Declines in Colorectal Cancer Incidence and Mortality Rates Slow Among Older Adults	33
Reply	33
Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States	33
Symptom Classes in Decompensated Liver Disease	33
Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy	33
Approach to Dietary Restriction in Irritable Bowel Syndrome	33
Nature and Nurture in Familial Aggregation of Steatotic Liver Disease	33
Elsewhere in the AGA Journals	33
Diagnosis of Retrograde Cricopharyngeus Dysfunction Using High Resolution Impedance Manometry and Comparison With Control Subjects	33
Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study	33
Repeating Ultrasound for Hepatocellular Carcinoma Detection in Case of Inadequate Liver Visualization: A Matter of Expertise	33
Diffuse Large B-Cell Duodenal Lymphoma Presenting With Obstruction and Pneumatosis	33